Drug Profile
Research programme: liver therapeutics - Nucorion Pharmaceuticals
Alternative Names: NUC-101; NUC-202; NUC-404Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Nucorion Pharmaceuticals
- Developer Ligand Pharmaceuticals; Nucorion Pharmaceuticals
- Class Antineoplastics; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C; Liver cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-B in China
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-C in China
- 28 Aug 2020 No recent reports of development identified for preclinical development in Liver-cancer in China